Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.42
-0.0100-0.70%
Pre-market: 1.38-0.0396-2.79%08:45 EDT
Volume:112.27K
Turnover:157.61K
Market Cap:22.46M
PE:-1.80
High:1.49
Open:1.41
Low:1.38
Close:1.43
52wk High:2.35
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:1.59
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7895
EPS(LYR):-0.7811
ROE:-157.09%
ROA:-25.31%
PB:6.35
PE(LYR):-1.82

Loading ...

Allarity Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14

Allarity Therapeutics Q2 Net Loss Per Share $0.21

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Q2 Operating Expenses USD 2.671 Million

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewswire
·
Aug 14

Allarity Therapeutics Inc Expected to Post a Loss of 25 Cents a Share - Earnings Preview

Reuters
·
Aug 13

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

GlobeNewswire
·
Jul 07

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib Drp® Companion Diagnostic

Reuters
·
Jul 06

Allarity Therapeutics - Has Patent Protection for Stenoparib Drp in Europe and Australia into 2039

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics - Granted Patent Term Extends into April 2042

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

GlobeNewswire
·
Jun 30

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress

Reuters
·
Jun 22

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

TIPRANKS
·
Jun 18

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO Gynaecological Cancers Congress 2026

Reuters
·
Jun 18

Allarity Therapeutics sets CEO consulting pay at SEK 6 million plus USD 163,043 for 2026 under amended services agreement

Reuters
·
Jun 03

Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

THOMSON REUTERS
·
May 16

Allarity Therapeutics Q1 FY26 net loss narrows to $2.75 million

Reuters
·
May 16

Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement

Reuters
·
May 12

Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026

Reuters
·
May 08